#1 Selling EndoAVF System*

Meet the WavelinQ™ EndoAVF System

The WavelinQ™ EndoAVF System joins the comprehensive BD product portfolio of devices and innovative solutions for creating and maintaining a patient’s AV access. After merging with Bard, a known leader in the ESKD market, BD continues to build on more than 40 years of developing unique solutions for clinicians and patients.

The WavelinQ™ EndoAVF System offers physicians a non-surgical alternative for AV fistula creation. Using two thin, flexible, magnetic catheters and a burst of RF energy, proceduralists can create an endovascular AV fistula. WavelinQ™ EndoAVFs offer two additional forearm AV fistula creation sites, and six times fewer post-creation interventions per patient year.1,2

Lorem ipsum dolor sit amet, consectetur

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

CTA

Lorem ipsum dolor sit amet, consectetur

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

CTA

Fill out this form to learn more about adding the #1 Selling EndoAVF System* to your practice.

When you add endovascular AV fistula creation to your AV access service, you join a community. BD will be there with training and support to build your endoAVF program, offering physician training courses, peer-to-peer best practice sharing, and local case support from patient selection to cannulation.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Day, Month date, time

Name
Title

Name
Title

Name
Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Day, Month date, time

Name
Title

Name
Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CTA

Video title here

Play

Lorem ipsum dolor sit amet, consectetur adipiscing

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

Lorem ipsum dolor sit amet, consectetur adipiscing elit
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse

CTA

St. Mary's Health & WavelinQ™ EndoAVF System

SSM St. Mary HCPs talks about access and the WavelinQ™ EndoAVF as an alternate option for fistula creation.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit,

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

SAT  |  JULY 11  |  10AM

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

REFERENCES

http://www.bardpv.com/WavelinQ4FrP-IFU.php

*In the US, calculated based on dollar sales. IQVIA Data total based on a hospital sample from Q1 2019 through Q3 2020 market share data. Data on file. Bard Peripheral Vascular, Inc. Tempe, AZ.

1Compared to surgical AV fistula creation.
2 Yang S, Arnold R, Lok C, Rajan D, Glickman M. J Vasc Access 2017; 18(Suppl. 2): 8-14. As demonstrated with the WavelinQ™ 6F EndoAVF System compared to a propensity-score matched surgical AVF cohort, comprised of a 5% CMS sample of claims data . N=60 for each. Total Intervention Rate of 3.4 versus 0.6, respectively
The WavelinQ™ EndoAVF System is indicated for the creation of an arteriovenous fistula (AVF) using concomitant ulnar artery and ulnar vein or concomitant radial artery and radial vein in patients with minimum artery and vein diameters of 2.0 mm at the fistula creation site who have chronic kidney disease and need hemodialysis. The WavelinQ™ EndoAVF System is contraindicated in target vessels <2mm in diameter.
Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions.

© 2021 BD. BD, the BD Logo, and WavelinQ are trademarks of Becton, Dickinson and Company or its affiliates. Illustrations by Mike Austin. © 2021. All Rights Reserved.